MedTrace Logo

Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis

NCT00951548 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2009-08-04

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo controlled study to assess the beneficial effects of food supplementation with VSL#3 as a support to standard pharmaceutical therapy in patients affected by mild to moderate active ulcerative colitis.

Conditions

Interventions

DIETARY_SUPPLEMENT

VSL#3

Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks

DIETARY_SUPPLEMENT

Placebo

Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks

Sponsors & Collaborators

  • VSL Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Claudio De Simone, Prof. · VSL Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Completion
2008-10-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00951548 on ClinicalTrials.gov